semaglutide tablets starting dose Wegovy® Dosing Information Semaglutide for Weight Loss |

is a member of the Advisory Boards of Novo Nordisk on insulin

Fortin and Roitman, 2017

Relevant disclosures: None Pearls Notes References Guest Profiles Production Team Pearls REDUCE-IT The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) trial was a large randomized controlled trial that showed a significant reduction in atherosclerotic cardiovascular disease (ASCVD) events with use of icosapent ethyl ester in secondary prevention patients and high risk primary prevention patients with diabetes and residual elevated triglycerides between 135 to 499 mg/dL on top of maximally tolerated statin therapy 1

doi: 10.1016/j.ejphar.2008.02.048 [DOI] [PMC free article] [PubMed] [Google Scholar] 13.Maciejczyk M, ebrowska E, Chabowski A

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: From discovery to clinical proof of concept